137 related articles for article (PubMed ID: 28025080)
1. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma.
Krencz I; Sebestyén A; Fábián K; Márk Á; Moldvay J; Khoor A; Kopper L; Pápay J
Hum Pathol; 2017 Apr; 62():66-73. PubMed ID: 28025080
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
3. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
4. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression.
Sticz T; Molnár A; Márk Á; Hajdu M; Nagy N; Végső G; Micsik T; Kopper L; Sebestyén A
J Clin Pathol; 2017 May; 70(5):410-416. PubMed ID: 27729429
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
7. Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.
Melling N; Simon R; Izbicki JR; Terracciano LM; Bokemeyer C; Sauter G; Marx AH
Int J Clin Exp Pathol; 2015; 8(6):7009-15. PubMed ID: 26261591
[TBL] [Abstract][Full Text] [Related]
8. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
9. mTOR pathway as a potential target in a subset of human medulloblastoma.
Pócza T; Sebestyén A; Turányi E; Krenács T; Márk A; Sticz TB; Jakab Z; Hauser P
Pathol Oncol Res; 2014 Oct; 20(4):893-900. PubMed ID: 24737380
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.
Machado LE; Alvarenga AW; da Silva FF; Roffé M; Begnami MD; Torres LFB; da Cunha IW; Martins VR; Hajj GNM
J Histochem Cytochem; 2018 Jun; 66(6):403-414. PubMed ID: 29328863
[TBL] [Abstract][Full Text] [Related]
11. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
12. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
14. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
16. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
Yoon MS
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
18. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
20. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
